Absinta, Martina http://orcid.org/0000-0003-0276-383X
Maric, Dragan http://orcid.org/0000-0003-2912-7921
Gharagozloo, Marjan http://orcid.org/0000-0002-2166-4012
Garton, Thomas http://orcid.org/0000-0001-9352-8530
Smith, Matthew D.
Jin, Jing http://orcid.org/0000-0003-1508-8036
Fitzgerald, Kathryn C. http://orcid.org/0000-0003-3137-0322
Song, Anya http://orcid.org/0000-0002-0885-7530
Liu, Poching
Lin, Jing-Ping http://orcid.org/0000-0003-0686-0215
Wu, Tianxia
Johnson, Kory R.
McGavern, Dorian B. http://orcid.org/0000-0001-9568-545X
Schafer, Dorothy P. http://orcid.org/0000-0003-2201-6276
Calabresi, Peter A.
Reich, Daniel S. http://orcid.org/0000-0002-2628-4334
Article History
Received: 30 November 2020
Accepted: 10 August 2021
First Online: 8 September 2021
Competing interests
: The authors declare no competing interests. M.A. received consulting fees from Sanofi, unrelated to this study. P.A.C. received grant support from Annexon Biosciences for testing the anti-C1q-blocking antibody in EAE. The funders of the study had no role in the collection, analysis, or interpretation of data, in the writing of the manuscript, or in the decision to submit the paper for publication.